Hong Kong, 23 March 2026 — Dingdang Health Technology Group Ltd. reported no change in its issued share capital while providing an updated tally of share repurchases carried out under its current mandate.
Key highlights 1. Share Capital Stability • Issued shares (excluding treasury shares) stood unchanged at 1.32 billion as of 23 March 2026. • No treasury shares were held, and no new shares were issued during the period.
2. Latest Repurchase Details (23 March 2026) • Volume: 647,000 ordinary shares. • Purchase method: On-market transactions on the Hong Kong Stock Exchange. • Price range: HKD 0.79 – HKD 0.81 per share, implying a volume-weighted average price of HKD 0.8047. • Aggregate consideration: HKD 0.52 million. • All shares are designated for cancellation.
3. Cumulative Activity Since 25 November 2025 • Total shares repurchased for cancellation but not yet cancelled: 24.64 million, equal to 1.87 % of the company’s issued shares on the mandate date (28 May 2025). • Estimated aggregate consideration for these buybacks: approximately HKD 27.18 million, implying an average outlay of roughly HKD 1.10 per share across 37 on-market transactions. • The repurchase mandate authorises up to 131.95 million shares; the company has utilised about 18.67 % of this limit.
4. Regulatory Framework • The repurchase programme was authorised by shareholders on 28 May 2025 and executed in compliance with Hong Kong Main Board Rules 10.06 and 13.25A. • A 30-day moratorium restricts any new share issues or treasury-share sales until 22 April 2026 following the latest buyback.
The company’s ongoing buyback activity underscores its continued utilisation of the approved mandate while maintaining a stable share base ahead of the cancellation of the repurchased shares.
Comments